Replies to post #468 on Celator Pharmaceuticals (CPXX)

[crudeoil24]

This summer CPXX should have FDA grant license for sales/marketing >>> Should hit price target then:

Roth Capital reiterated a Buy rating on Celator Pharmaceuticals (NASDAQ: CPXX), and raised the price target to $18.00 (from $15.00). Analyst Joseph Pantginis believes that there is disconnect in regards to share price and fundamental opportunity for Vyxeos.

Pantginis commented, "We believe a significant disconnect exists with regard to CPXX' share price and the fundamental opportunity for Vyxeos. We believe Vyxeos represents the first potential meaningful improvement to treating AML in decades, and believe clinical data to date support our thesis. Reiterate Buy and target upped to $18 from $15 as we introduce our market model for the potential first indication."

Pantginis also added, "Celator has reached the end of a long wait and has set the stage for what we project will be a positive outcome to the Phase III sAML program with Vyxeos (CPX-351) in 1Q16. We are introducing our market model for the initial indication as well as our updated clinical NPV model which drives our new price target of $18 (from $15)."

[INTL]

Hold
It will get there
Good luck